Physician profile
Rex B Mowat
NPI 1346247251
$118,371.56
in general payments reported to CMS, 2019-2025
69 companies · $3,287 in 2025
The $3,287 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,344 · 2020: $49K · 2021: $5,194 · 2022: $17K · 2023: $37K · 2024: $2,206 · 2025: $3,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Honoraria: $15K · Food and Beverage: $3,952 · Travel and Lodging: $2,998 · Education: $243 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,336.25 |
| Honoraria | $14,800.00 |
| Food and Beverage | $3,951.89 |
| Travel and Lodging | $2,998.34 |
| Education | $243.18 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $224.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $69,030.30 | 2019-2025 | Enhertu, Datroway |
| Cornerstone Specialty Network LLC | $42,608.95 | 2019-2024 | |
| Geron Corporation | $960.00 | 2025 | Rytelo |
| Incyte Corporation | $774.93 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $551.37 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Janssen Biotech, INC. | $308.90 | 2019-2025 | Erleada, Imbruvica, Rybrevant |
| Genzyme Corporation | $301.39 | 2021-2025 | |
| Foundation Medicine, INC. | $300.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $285.00 | 2019-2025 | |
| Tempus Ai, INC | $259.58 | 2024-2025 | Xt Cdx |
| Seagen INC. | $255.95 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Merck Sharp & Dohme LLC | $254.36 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $200.32 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $180.42 | 2020-2025 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $163.86 | 2021-2024 | Opdivo, Reblozyl |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $146.64 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Stemline Therapeutics INC. | $140.87 | 2022-2025 | Orserdu |
| Gilead Sciences, INC. | $132.36 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $131.31 | 2019-2025 | Padcev, Vyloy, Xospata |
| Genmab U.S., INC. | $117.65 | 2024 | Epkinly |
| Abbvie INC. | $93.47 | 2022-2025 | |
| Dova Pharmaceuticals | $92.42 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $75.29 | 2022 | |
| Varian Medical Systems, INC. | $70.55 | 2019 | |
| Eisai INC. | $67.67 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $65.79 | 2022-2025 | Clonoseq |
| Genentech USA, INC. | $63.69 | 2019-2025 | Itovebi |
| Lilly USA, LLC | $59.82 | 2022-2024 | Retevmo, Jaypirca, Verzenio |
| Beone Medicines USA, INC. | $59.79 | 2025 | Brukinsa |
| Elekta, INC. | $58.38 | 2019 | |
| Pfizer INC. | $57.85 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $55.24 | 2019-2024 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $48.05 | 2023-2024 | |
| G1 Therapeutics, INC. | $46.20 | 2022-2023 | Cosela |
| Rigel Pharmaceuticals, INC. | $45.01 | 2021-2023 | Rezlidhia, Tavalisse |
| Morphosys, US INC. | $40.69 | 2023 | Monjuvi |
| Dendreon Pharmaceuticals LLC | $34.99 | 2024 | Provenge |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Libtayo |
| Tersera Therapeutics LLC | $29.92 | 2025 | Zoladex |
| Adc Therapeutics America, INC. | $25.67 | 2025 | |
| Array Biopharma INC | $23.15 | 2024 | Braftovi, Lorbrena, Xalkori |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Tolmar, INC. | $19.48 | 2025 | Rubraca |
| Pharmaand Gmbh | $19.48 | 2025 | Rubraca |
| Apellis Pharmaceuticals, INC. | $17.18 | 2022 | |
| Kyowa Kirin, INC. | $14.72 | 2025 | |
| Amneal Pharmaceuticals LLC | $14.65 | 2024 | Avastin |
| Kite Pharma, INC. | $14.21 | 2024 | Yescarta |
21 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$89,600.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Mowat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.